Astellas Pharma Inc 2023 IR
The report outlines Astellas' financial and non-financial performance for the fiscal year ended March 31, 2023. Key highlights include the acquisition of Iveric Bio to strengthen its ophthalmology capabilities and the FDA approval of VEOZAH for treating vasomotor symptoms due to menopause. The company made significant progress toward its sustainability goals, achieving its existing 2030 greenhouse gas emissions reduction targets early and committing to net-zero emissions by 2050. Additionally, Astellas advanced its organizational health goals, showing improved employee engagement and promoting a flatter organizational structure to accelerate innovation.
Company: Astellas Pharma Inc
Sector: Health Care
Country: Japan
Year: 2023
Type: IR
Pages: 100
Astellas Pharma Inc
Integrated Report
The report outlines Astellas' financial and non-financial performance for the fiscal year ended March 31, 2023. Key highlights include the acquisition of Iveric Bio to strengthen its ophthalmology capabilities and the FDA approval of VEOZAH for treating vasomotor symptoms due to menopause. The company made significant progress toward its sustainability goals, achieving its existing 2030 greenhouse gas emissions reduction targets early and committing to net-zero emissions by 2050. Additionally, Astellas advanced its organizational health goals, showing improved employee engagement and promoting a flatter organizational structure to accelerate innovation.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Apr 1, 2022 - Mar 31, 2023
Fiscal Year
2022
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Net Zero Target
Employees